Background {#Sec1}
==========

Germ-line inactivating mutations in the breast cancer susceptibility gene *BRCA1* (OMIM\#113705) confer a marked hereditary predisposition to breast and ovarian cancer (HBOC). Yet, the role of *BRCA1* as a driving gene in sporadic breast cancer is, at best, far from clear. Early studies identified a very low proportion of somatically acquired *BRCA1* inactivating mutations in sporadic breast cancer \[[@CR1]\]. Recent efforts aimed at elucidating the cancer genome have confirmed this view. According to the COSMIC database (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>; last accessed 08/01/2015), *BRCA1* somatic mutations are very rare, regardless of the breast cancer subtype analyzed (0.61% of breast cancer samples overall, 0.44% of basal-like breast cancers). While the analysis of somatic mutations does not support a major role for *BRCA1* in sporadic breast carcinogenesis, other evidences suggest that altered transcriptional regulation, rather than somatic mutations, might be involved in breast carcinogenesis \[[@CR2]-[@CR4]\]. For instance, it has been reported that sporadic basal-like tumors frequently down regulate *BRCA1* expression \[[@CR2]\]. As far as we know the role of other possible *BRCA1* inactivating mechanisms (such as splicing alterations) in breast carcinogenesis has not been comprehensively explored.

Recently, the ENIGMA consortium has analyzed naturally occurring *BRCA1* alternative splicing (AS) in blood related RNA sources (commonly used for clinical splicing assays) \[[@CR5]\], identifying up to 63 AS events, and supporting an AS model in which most non-mutually exclusive AS events are randomly combined into individual mRNAs molecules to produce probably hundreds of different RNA isoforms. To what extent these findings are tissue specific is not known. The ENIGMA study suggested that AS at the *BRCA1* locus is similar in blood and healthy breast tissue, albeit only one healthy breast tissue was available (one breast epithelia sample from a cosmetic surgery), thus limiting the power of the analysis \[[@CR5]\].

In the present study, we have employed approaches previously developed by the ENIGMA consortia \[[@CR5]\] to perform a comprehensive characterization of AS at the *BRCA1* locus in a cohort of 70 breast tumor samples from patients diagnosed as having locally advanced breast cancer, enrolled in a neoadjuvant clinical trial and whose tumors have been classified into intrinsic subtypes. For comparative purposes, we have characterized as well AS in 72 blood samples from healthy control individuals and 4 healthy breast tissues (cosmetic surgeries). As far as we know, this is the most comprehensive description of AS at the *BRCA1* locus reported so far in human breast cancer samples.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Tumor biopsy specimens were obtained from a set of 70 pre-treated patients, diagnosed as having locally advanced breast cancer. These patients participated in a neoadjuvant clinical trial (registered at the following Web site: <http://www.clinicaltrials.gov>; identifier NCT00123929) in which they were randomly assigned to receive four cycles of either doxorubicin (75 mg/m^2^body surface area) or docetaxel (Taxotere, Sanofi-Aventis, Spain) (100 mg/m^2^body surface area) every 3 weeks followed by surgery \[[@CR6]-[@CR9]\]. The clinical trial was approved by the Hospital Clínico San Carlos Ethics Committee, Madrid, Spain. Briefly, eligibility criteria included the following: women aged between 18 and 78 years; clinical stage IIB, IIIA, or IIIB breast cancer; and palpable breast tumors not amenable to breast-preserving surgery. Before the start of the trial, an informed consent was obtained from all participants. Clinico-pathological features of the study population are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Additionally, breast tissue samples were obtained from four healthy individuals who underwent reduction mammoplasty. Similarly, whole blood was drawn from 72 healthy control donors (collected in EDTA tubes). All patients signed an informed consent for voluntary donation of biological samples for research to the Hospital Clínico San Carlos Biobank.

Laboratory analysis {#Sec4}
-------------------

Tumor biopsy specimens were obtained before neoadjuvant chemotherapy. To check cellularity, an H&E image was obtained from all tumors; only samples with more than 80% tumor cells were used. Total RNA was extracted using the kit Qiagen RNeasy Mini Kit (Qiagen Inc., Valencia, CA), following the instructions of the manufacturer. Blood samples were kept ice-cold for a maximum of 30 minutes before RNA extraction. Total RNA was extracted from whole blood (200 μL) using a MagnaPure Compact workstation and MagnaPure RNA Isolation Kit according to the manufacturer's protocol. The amount of RNA was assessed using a Nanodrop ND-1000 UV Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). RNA integrity was assessed using a kit (RNA 6000 Nano Chip kit), followed by analysis with Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Total RNA, 200 ng, was used as a template to obtain first-strand cDNA using SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Parsley, UK), following the manufacturer's instructions.

Comprehensive characterization of AS events at the *BRCA1* locus was performed by semi-quantitative capillary electrophoresis (capillary EP). The overall strategy has been reported elsewhere \[[@CR5]\]. For the purpose of this study, we define AS events as those incorporating splice junctions not present in the reference transcript Ensemble ENST00000357654 (hereafter referred to as full-length transcript). In brief, eight combinations of forward and reverse primers located at exonic regions (hereafter referred to as splicing assays) were used to amplify cDNAs that later were analyzed by capillary EP. Figure [1](#Fig1){ref-type="fig"} shows representative examples of each of the eight splicing assays. Primers sequences are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2. All assays were performed in a 25 ul reaction volume containing 1 ul of cDNA template, 2.5 ul of 10× PCR reaction buffer with 20 mM MgCl~2~ (Roche Diagnostics, Mannheim Germany), 0.2ul of FastStart Taq DNA polymerase (Roche Diagnostics, Mannheim Germany) 200 umol of each deoxynucleoside triphosphate and 0.25 umol of each primer. Thermal cycling consisted of an initial 10-minutes hold at 95°C, followed by 30-second hold at 95°C, 30-second hold at 58°C, and 60-second hold at 72°C for 33 cycles. In all cases, capillary EP analysis was performed in an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA) using 50 cm capillary arrays filled with POP-7 and GeneScan 500-LIZ (Applied Biosystems, Foster City, CA) as internal size-standard. A standard electrophoresis protocol was used in all cases (temperature 60°C, injection 15 sec at 1.6KVolts, and running 1800 sec at 15KVolts). Peak heights under 100 RFU (Relative Fluorescent Units) were not considered for analyses. Size-calling and peak areas were analyzed with GeneMapper software version 4.0 (Applied Biosystems, Foster City, CA). Peak annotation was performed as previously reported \[[@CR5]\].Figure 1**Representative examples of each of the eight cDNA splicing assays.** Peak heights represent fluorescence intensity (scale on relative fluorescent units (RFU)). GeneScan 500-LIZ standard peaks are colored in orange. Peaks imputed to AS events are colored in blue. Capillary EP analysis permitted us to identify peaks imputed to transcripts carrying more than one independent splicing. For instance, assay 1--6 demonstrated that Δ1Aq (6 bp shorter than the FL) is combined with most of the splicing events visualized in this amplicon. Similarly, a peak of 322 bp in 7-11B assay demonstrated the presence of transcripts containing Δ8p and Δ9,10. As shown in 7-11B assay Δ9,10 is 123 bp shorter than the FL. In 7--12 assay a peak of 361 bp can be imputed to the combination of Δ9,10+ Δ11q since this peak is 123 bp shorter than Δ11q peak.

Relative quantification of individual AS events (expressed as the average ratio between the peak area of that particular event and the peak area of the full-length signal in the corresponding assay) allowed us to classify AS events as *predominant* (≥10% of the full-length signal) or *minor* (\<10%). AS events detected by the exons 7--12 assay were not classifiable because the full-length reference transcript containing exon 11 (\>3300 bp) was not co-amplified. *BRCA1* exons were named according to the Breast Core Informative (BIC) database nomenclature \[[@CR10]\], so that the 22 coding exons of the reference full-length transcript are numbered from 2 to 24 with no exon 4 defined. We have designated splicing events as previously reported \[[@CR5],[@CR11],[@CR12]\] combining the following symbols: Δ (skipping), ▼ (retention), p (proximal), and q (distal). Structural and functional annotation of AS events was performed as previously described \[[@CR5]\]. Briefly, functional annotation of *BRCA1* AS events includes: Non-Coding (splicing events eliminating the full-length start codon), PTC-NMDs (splicing events introducing Premature Termination Codons predicted to induce the Nonsense-Mediated RNA Decay pathway), No-FS (in-frame splicing events), FS-alternative STOP (frame-shift events generating PTCs not predicted to induce NMD as they are located in the most downstream *BRCA1* exons) and UTRs (splicing events modifying Un-Translated Regions). Further on, based on functional annotation, we classify AS events into *likely inactivating* and *other* AS events. The former category, referring to AS events that render the corresponding transcript unable to codify for functional *BRCA1* proteins, includes Non-Coding and PTC-NMD events, as well as two in-frame splicing events that target the critical RING (Δ5) and BRCT (Δ18) functional domains. By contrast, No-FS, FS-alternative STOP, and UTR AS events, with no obvious functional interpretation, were considered collectively as *other* AS events.

IHC FISH, Tumor grading and subtype assignation {#Sec5}
-----------------------------------------------

Paraffin-embedded tumor samples from core biopsy specimens were evaluated by immunohistochemical analysis for estrogen receptor (ER) (clone 1D5, 1:35; Dako Cytomation, Glostrup, Denmark) and progesterone receptor (PR) (clone PgR 636, 1:50; Dako Cytomation). After incubation with the primary antibodies, immunohistochemical studies were performed using the Autostainer link 48 (Dako Cytomation, Carpinteria, CA). The cut points for ER and PR positivity were established at 1% or greater of stained cells. Slides of all tumors were reviewed for diagnostic reassessment of the tumor histotype and histological grade, in a blinded fashion. The amplification of *ERBB2* was measured by FISH (fluorescence in situ hybridization).The probes used were as follows: Centromere enumeration probe 17, labeled in green; and locus-specific identifier *ERBB2* probe, labeled in orange (Vysis-Abbott, Downers Grove, IL). Slides were prepared according to the manufacturer's instructions. A positive result was defined as an *ERBB2* gene/chromosome 17 ratio of 2.2 or greater. A minimum of 100 nuclei were counted per case.

Gene expression data from previously hybridized gene expression microarrays \[[@CR6],[@CR13]\] (available in the Gene Expression Omnibus repository database under accession number GSE21997) was used for intrinsic subtype assignment. Breast cancer molecular subtypes were identified using the PAM50 and the Claudin-low (CLP) subtype predictors as previously described \[[@CR14],[@CR15]\].

Statistical analysis {#Sec6}
--------------------

All analysis where restricted to the subgroup of predominant splicing events (events representing \>10% of the full-length signal in at least one tumor sample) exclusively. Association between two categorical variables was assessed using the *Χ*^2^ or Fisher exact test in cases in which more than 25% of the expected values were less than five. P-values were corrected for multiple comparisons using False Discovery Rate (FDR) method \[[@CR16]\]. For quantitative variables, comparisons were assessed by T-student test or Mann Whitney test when appropriate. P \< 0.05 was considered for statistical significance. The statistical analysis was performed using software R 3.0.1.

Results {#Sec7}
=======

Overall, we have identified in breast tissue samples most of the *BRCA1* AS events previously identified by the ENIGMA consortium in blood-derived samples (54 out of 63, see Additional file [1](#MOESM1){ref-type="media"}: Table S3) \[[@CR5]\]. As previously observed \[[@CR5]\], most AS events were rather minor in most analyzed samples, with the notable exception that Δ1Aq, Δ8p, Δ9,10, Δ14p and Δ5q (Table [1](#Tab1){ref-type="table"}) were frequently identified as *predominant* AS events, regardless of the tissue of origin. Further on, the relative quantification of these AS events is similar in breast tumor and blood samples, with Δ1Aq expressed on average at similar levels than the full-length reference and Δ8p, Δ9,10 and Δ14p, signals representing roughly 35%. Nonetheless, Δ5q levels were higher in breast tumor samples (P \< 0.01) (Figure [2](#Fig2){ref-type="fig"}). Equally relevant, we have not identified any breast specific AS event, neither in healthy nor in malignant samples. Taken together, the data suggests that, AS events at the *BRCA1* locus in human breast tissue and blood are similar, with no evidence for tissue specific AS events. These observations support the clinical use of blood samples as an adequate surrogate for testing the spliciogenic effect of *BRCA1* genetic variants. Further on, our data suggests as well that somatic inactivation of *BRCA1* through the acquisition of spliciogenic mutations is, at best, an uncommon mechanism in breast carcinogenesis.Table 1**Predominant splicing events distribution by tissue***Breast tumorHealthy breast tissueBlood-derived samplesVariant nameHGVS descriptionFunctional annotationBiotypeFrequency predominantFrequency predominantP* ^*1*^*Frequency predominantP* ^*2*^**Δ8p**c.442_444del3No FSSplice acceptor shifts1.0001.000NS1.000NS**Δ14p**c.4358_4360del3No FSSplice acceptor shifts1.0001.000NS1.000NS**Δ1Aq**c.-25\_-20del6UTRSplice donor shifts1.0001.000NS1.000NS**Δ9,10**c.548_670del123No FSmulti-cassette0.9711.000NS0.988NS**Δ5q**c.191_212del22PTC-NMDSplice donor shifts0.8570.750NS0.3910.001**Δ13**c.4186_4357del172PTC-NMDCassette0.3570.000NS0.0000.049**Δ9**c.548_593del46PTC-NMDCassette0.2030.000NS0.0000.0175**Δ5**c.135 \_212del78No FSCassette0.2000.250NS0.0000.0001**Δ2**c.-19_80del99Non-CodingCassette0.2000.250NS0.333NS**▼1aA**c.-20 + 1\_-20 + 89ins89UTRSplice donor shifts0.1570.000NS0.0000.006**Δ22**c.5333_5406del74FS-alternative STOPCassette0.1290.000NS0.031NS**Δ2p**c.-19\_-7del13UTRSplice acceptor shifts0.1140.000NS0.059NS**Δ10**c.594_670del77PTC-NMDCassette0.0870.000NS0.0000.07**▼4**c.135-4047_135-3932ins116PTC-NMDCassette0.0860.000NS0.0000.07**Δ8_10**c.442_670del229PTC-NMDmulti-cassette0.0720.000NS0.0000.082**Δ3**c.81_134del54PTC-NMDCassette0.0710.000NS0.071NS**Δ21**c.5278_5332del55PTC-NMDCassette0.0710.000NS0.000NS**Δ15**c.4485_4675del190PTC-NMDCassette0.0710.000NS0.000NS**Δ21_23**c.5278_5467deFS-alternative STOPmulti-cassette0.0710.000NS0.034NS**Δ2,3**c.-19_134del153Non-Codingmulti-cassette0.0430.000NS0.023NS**▼13A**c.4358-2785_4358-2729ins66No FSCassette0.0430.000NS0.000NS**Δ21,22**c.5278_5406del129No FSmulti-cassette0.0430.000NS0.000NS**Δ8,9**c.442_593del152PTC-NMDmulti-cassette0.0140.000NS0.000NS**Δ17**c.4987_5074del88PTC-NMDCassette0.0140.000NS0.000NS**Δ22,23**c.5333_5467del135FS-alternative STOPmulti-cassette0.0140.000NS0.000NS**Δ13p**c.4186_4188del3No FSSplice acceptor shifts0.0140.000NS0.000NS**Δ15_17**c.4485_5074del590PTC-NMDmulti-cassette0.0140.000NS0.000NSP^1^ for significance of Fisher exact test for differences between observed and expected values of AS events frequency distribution in breast tumor samples and healthy breast samples. P^2^ for significance of ×^2^ statistic or Fisher exact test, when appropriate, for differences between observed and expected values of AS events frequency distribution in breast tumor samples and blood-derived samples. Note that none of the 27 AS events listed is annotated more frequently as predominant in blood- derived sample.Figure 2**Relative quantification of predominant splicing events. (A)**. The chart shows the ratios between peak areas of alternative splicing events and peak areas of the reference full-length transcripts in tumor samples (T) and blood-derived samples **(B)**. \*(P \< 0.01) **(B)**. Representative example of a cDNA splicing assays showing Δ1Aq, Δ8p, Δ9,10 and, Δ14p peak areas (blue). The assay allowed us to identify transcripts with different combinations of splicing events such as Δ9, 10 + Δ8p. Interestingly, the assay predicts the existence of another splicing event involving ±16 bp (X in the figure).

While the above data indicates that, on average, AS at the *BRCA1* locus is similar in breast and blood samples, Δ5q findings prompted us to explore the possibility that more subtle splicing alterations targeting individual AS events in individual breast tumor samples do exist. To begin with, we have identified up to 27 AS events that were annotated as *predominant* (\>10% of the reference full-length signal) in at least one tumor sample (Table [1](#Tab1){ref-type="table"}). Focusing on individual AS events, we found that seven (Δ5q, Δ13, Δ9, Δ5, ▼1aA, Δ10 and ▼4, all of them *likely inactivating*) were more frequently annotated as predominant in breast tumor samples than in blood-derived samples, albeit in the case of Δ10 and ▼4 the findings did not reach statistical significance (Table [1](#Tab1){ref-type="table"}). After FDR correction, the differences in Δ5q and Δ5 frequency distribution between blood and tumor samples remained significant (P = 0.014 and P = 0.003 respectively).

Similarly, we observed that, on average, the absolute number of predominant splicing events per sample was higher in tumor samples than in healthy breast tissue samples (6.8 vs. 5.0; P = 0.010). The same was true for peaks corresponding to the combination of two or more splicing events (8.9 vs. 5.7; P = 0.004). Additionally, we found that *likely inactivating* AS events were, on average, more frequently annotated as predominant in breast tumor samples than in healthy breast samples (2.6 vs 1.0; P = 0.020), while the same effect was not true for *other* AS events (4.1 vs 4.0; P = 0.689). Some representative examples of *likely inactivating* AS events occurring in breast tumor samples are displayed in Additional file [1](#MOESM1){ref-type="media"}: Figure S1. Overall, the data suggests an excess of *likely inactivating* AS events in breast cancer cells.

Finally, we explore the possibility that certain AS events annotated as predominant in individual tumor samples were associated with the intrinsic subtype, as defined by PAM50 + CLP genomic profiling, but we did not identify any obvious association.

Discussion {#Sec8}
==========

To our knowledge, this is the most comprehensive description of AS at the *BRCA1* locus reported so far in human breast samples. To perform this analysis, we took advantage of recent studies conducted by the ENIGMA consortium for the characterization of naturally occurring AS at the *BRCA1* locus in blood related samples \[[@CR5]\]. According to the ENIGMA consortium, pervasive AS at the *BRCA1* locus is observed in blood related samples, with up to 63 individual AS events identified \[[@CR5]\]. This observation was consistent with several genome-wide analyses that have identify a strong association of high level AS loci with intrinsically disordered protein/domains (IDPs/IDDs), IDPs/IDDs with Hub proteins, and Hub proteins with disease \[[@CR17]-[@CR19]\].

In the present study, we analyze to what extent this high level of AS is observed also in breast related samples. With this aim, we have characterized *BRCA1* AS in 70 breast tumor samples and 4 healthy breast tissue samples. For ethical reasons, it is difficult to access healthy human breast samples, so that we have performed the study in a very small cohort. Overall, our study concludes that AS at the *BRCA1* locus is similar in breast and blood samples. First, most AS events previously identified in blood, 54 out of 63, have been identified as well in healthy and tumor breast samples. Second, we have not identified any novel AS event not previously described in blood. Third, up to four AS events (Δ1Aq, Δ8p, Δ9,10, Δ14p) emerge as *predominant* in almost all samples of both tissues. Four, the relative semi-quantification of these *predominant* AS events reveals similar profiles in both tissues, with Δ1Aq representing roughly 90% of the reference full-length signal, Δ8p, Δ9,10, and Δ14p representing 30% (Figure [2](#Fig2){ref-type="fig"}). As a corollary, we conclude that somatic inactivation of *BRCA1* through spliciogenic mutations is, at best, a rare mechanism in breast carcinogenesis.

We have concluded that, on average, AS at the *BRCA1* locus in breast and blood samples is very similar. Yet, in the present study we addressed as well the possibility that subtle quantitative alterations involving certain AS events were detectable in individual breast tumor samples. Due to the complexity of such analysis, in the present study we have restricted ourselves to compare the average number of *predominant* AS events detected in individual breast and blood samples. Interestingly, our data supports an excess of *predominant* AS events in tumor samples, in particular AS events annotated as *likely inactivating*. Since we have analyzed very few healthy breast samples, we cannot rule out the possibility that this finding (and excess of *likely inactivating* AS events in breast tumor samples) reflects tissue specific AS regulation, rather than a tumor specific phenotype acquired in the carcinogenic process. Further on, according to our data *likely inactivating* splicing events are not associated with any particular breast cancer subtype. Splicing deregulation represents a relevant ethiopathogenic mechanism of some diseases, including cancer \[[@CR20]\]. Yet, further studies are needed to establish a role, if any, for *BRCA1 likely inactivating* AS events in sporadic breast carcinogenesis.

A catalogue of AS events occurring at the *BRCA1* locus in breast tissue sample is an essential requirement for the design of adequate RNA splicing assays assessing the pathogenicity of *BRCA1* sequence variants. Indeed, our findings of similar AS events in breast and blood samples somehow validate the use of blood-derived samples for *in vitro* splicing assays testing the clinical relevance of *BRCA1* sequence variants, a key issue in molecular diagnosis \[[@CR12]\]. In addition, the results presented here will help researchers to analyze and validate data from RNAseq experiments that are becoming increasingly widespread. Moreover, tools for functional annotations of novel sequences (novel transcripts) and the analyses of annotation data are clearly warranted. In this way, our data might be useful for the development of such tools.

Conclusions {#Sec9}
===========

Our results complement recent findings by the ENIGMA consortium, demonstrating that *BRCA1* AS, despite its tremendous complexity, is very similar in breast and blood samples, with no evidences for tissue specific AS events. Further on, we conclude that somatic inactivation of *BRCA1* through spliciogenic mutations is, at best, a rare mechanism in breast carcinogenesis, albeit our data detects an excess of *likely inactivating* AS events in breast tumor samples.

Additional file {#Sec10}
===============

Additional file 1: Table S1.Clinicopathological characteristics of the 70-breast tumor sample cohort. **Table S2.** Primer sequences and full length fragment size. **Table S3.** Splicing events previously identified in blood-derived samples. The 2^nd^ column indicates whether the splicing event have been cloned and sequenced or directly sequenced from the splicing assay (yes) or imputed to predicted size-fragments according to Ensemble reference transcript ENST00000357654 (no). For further details see reference \[5\]. The 3^rd^ column shows the AS events that have been detected in at least one sample of the present study. Not analyzed refers to AS events that couldn't be identified by the analytical approach carried out. **Figure S1.** PTC-NMD predominant splicing events in breast tumor samples.
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